UCB (OTCMKTS:UCBJF) Trading Down 11.9% – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s share price dropped 11.9% during trading on Friday . The stock traded as low as $260.3250 and last traded at $260.3250. 4 shares were traded during trading, a decline of 99% from the average daily volume of 746 shares. The stock had previously closed at $295.59.

Analyst Upgrades and Downgrades

Separately, Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

UCB Trading Up 3.8%

The firm’s fifty day moving average price is $292.35 and its 200-day moving average price is $300.27. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.